Giving a voice to people who are facing #MBC is important and often underserved in topics such as side effects, sexual health, and quality of life. That's why we support organizations like Breastcancer.org.

To learn more about their mission, visit breastcancer.org/managing-life/…

ANNOUNCEMENT! We are pleased to announce the publication of ELAINE-1 and ELAINE-2 trial results in Annals of Oncology.

Read more in the official press release: sermonixpharma.com/news/
#BCSM

Were you unable to attend SABCS? We contributed 5 poster presentations to this year’s conference. #ICYMI (or if you just want a second look) you can review all 5 right here: sermonixpharma.com/medical-meetin…

Are you attending SABCS? We’re pleased to contribute 5 poster presentations at this year’s conference. Let us know if we’ll see you there.

For all the details, dates, and times, please read the #SABCS23 press release: bit.ly/3NaImIf

We are pleased to add to the significant body of literature in the ER+/HER2- mBC arena with a new publication in JCO Precision Oncology. Review the press release for more information about the new case report: bit.ly/3QP7Mxj
#BCSM #ELAINEStudies

At Sermonix, we aim to extend hope and quality of life to patients with metastatic breast cancer (mBC). Clinical trials are key to bringing treatment advances to these patients. Learn more about our #ELAINEStudies . bit.ly/458Lo66 #MBC AwarenessDay #MBC

We proudly presented 2 posters addressing the sexual and urogenital health of patients with metastatic breast cancer at last week’s The Menopause Society Annual Meeting in Philadelphia.

#ICYMI Review the data from both poster presentations now: bit.ly/3PrrbTi…

Don’t miss the second of our 2 poster presentations at the The Menopause Society Annual Meeting. It summarizes results from the EQUALS 2 survey—providing greater understanding of the vaginal/sexual health concerns in patients with ER+/HER2- #MBC . #ELAINEStudies #BCSM

We are proud to announce the first of 2 poster presentations at the The Menopause Society Annual Meeting in Philadelphia next week—examining baseline vaginal and vulvar symptoms in patients with ESR1-mutated, ER+/HER2- metastatic breast cancer. #ELAINEStudies #BCSM

#ICYMI . Check out the encore ELAINE-2 abstract which was presented at the Metastatic Breast Cancer Research Conference (MBCRC).

Review the abstract here: bit.ly/3Z8z846
#ELAINEStudies #MBCRC

Meet Maimah Karmo, CEO of the Tigerlily Foundation a national women’s health and oncology organization providing education, awareness, advocacy, and hands-on support to young women – before, during, and after cancer. Read the full interview: linkedin.com/feed/update/ur…
#SermonixSpotlight

Check out the article in JCO Clinical Cancer Informatics analyzing our use of both traditional enrollment methods and a just-in-time model for our phase 2 ELAINE-2 clinical trial. Read the full article. bit.ly/3PLt8f0

#BCSM #ELAINEStudies

Today, we shine our #SermonixSpotlight on Dr. Lisa Larkin, founder and CEO at Ms.Medicine, who spoke to us about developing a new model of care for women, the need for better breast cancer risk assessment, and conquering #Kilimanjaro .

Read the full interview:…

Did you know most women with cancer experience some degree of sexual dysfunction? Check out this article, which details why oncology providers have a “duty” to address it. bit.ly/44e9jRk

Visit our site to see how lasofoxifene impacts vaginal health. #MBC #ELAINEstudies

#ICYMI , view our abstract from #ASCO2023 , “Lasofoxifene plus abemaciclib for treating ESR1-mutated ER+/HER2- metastatic breast cancer after progression on prior therapies,” online.
ASCO now recommends routine testing for the emergence of ESR1 mutations. bit.ly/3J2DaEk

For National Cancer Survivors Day, we spoke with Lisa Larkin—medical doctor, founder and CEO at Ms.Medicine, and breast cancer survivor—what survivorship really means.

Come back soon to read the full interview.

#CelebrationOfLife #BreastCancerSurvivors #CancerSurvivorsDay

ASCO now recommends routine testing for the emergence of ESR1 mutations.

Join us for our abstract presentation: “Lasofoxifene plus abemaciclib for treating ESR1-mutated ER+/HER2- metastatic breast cancer after progression on prior therapies.” #MBC bit.ly/3oqHZjT

We continue celebrating moms and women during National Women’s Health Week and encourage women everywhere to focus on their health and well-being.

See how we prioritize the health of women living with #MBC . elainestudy.com

#ELAINEstudies #NWHW